drugset
Drugs / DL-2-(difluoromethyl) ornithine monohydrochloride
last change Dec 2024 re-read 2 minutes ago

DL-2-(difluoromethyl) ornithine monohydrochloride

also known as DFMO
Developed for
breast cancer · cervical cancer · colorectal cancer · diffuse midline glioma, H3 K27M-mutant · endometrial cancer · esophageal cancer · gastric cancer · head and neck cancer
+6 more · malignant peritoneal mesothelioma · malignant pleural mesothelioma · melanoma · non-small cell lung carcinoma · ovarian cancer · thyroid gland papillary carcinoma
Investigated by
Aminex Therapeutics, Inc.

Trials 1 · a red edge is where a trial was stopped

today NCT05500508 · Ph 1/2
2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT05500508 Nov 2022 → Dec 2024 breast cancer, cervical cancer, colorectal cancer, diffuse midline glioma, H3 K27M-mutant +10 Aminex Therapeutics, Inc. Terminated No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as DL-2-(difluoromethyl) ornithine monohydrochloride “DFMO is DL-2-(difluoromethyl) ornithine monohydrochloride monohydrate provided as a 200 mg/mL aqueous solution in 20 mL vials.” NCT05500508 ↗
Known as DFMO ClinicalTrials.gov intervention name — accepted as the source's own label NCT05500508 ↗
Route Intravenous “IV DFMO” NCT05500508 ↗